Skip to main content
ICPE 2023 Main banner
Final Program


ICPE 2023 Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Priya Bahri, PhD, PGDipEpi, RPh, FISoP

Dr.
European Medicines Agency
Amsterdam, Netherlands

Priya Bahri completed studies in pharmacy (University of Heidelberg) and epidemiology (McGill University) and a PhD in quality management of healthcare (Humboldt University Berlin). Her continued professional development include post-graduate certificates in strategic health communication (Johns Hopkins University) and global health diplomacy (Graduate Institute Geneva).

She had gained work experience in hospital and community pharmacies and projects for health insurance companies and for the German international development agency before joining the European Medicines Agency (EMA) in 1996. There she has had responsibilities for the co-ordination of the EU pharmacovigilance system and now is the EMA's lead for pharmacovigilance and risk management guidance and policy. This includes EU-GVP and research into communication and engagement of medicine users in support of evidence-based regulatory decision-making and implementation of risk minimisation measures in healthcare. In that role she collaborates closely with patient, healthcare professional, academic and industry organisations as well as internationally with non-EU regulators, WHO, UMC, CIOMS and ICH.

Pro bono, she is associated researcher at the Utrecht Centre for Pharmaceutical Policy and Regulation and an active member of the International Society of Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP), and she is editor of the book “Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research”, published by Springer in 2020.

AT ISPE, she is co-founder of the Special Interest Group on Benefit-Risk Assessment, Communication/risk minimisation and Evaluation (ISPE BRACE SIG) and since 2020 also member of the Public Policy Committee.

At ISoP, she is co-founder and coordinator of the Special Interest Group on Medicinal Product Risk Communication (ISoP CommSIG). In 2019, she was awarded as ISoP Fellow.

Disclosure information not submitted.

Presentation(s):